Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition

Curmi, 1999, Stathmin and its phosphoprotein family: general properties, biochemical and functional interaction with tubulin, Cell Struct Funct, 24, 345, 10.1247/csf.24.345 Verma, 2009, STAT3-stathmin interactions control microtubule dynamics in migrating T-cells, J Biol Chem, 284, 12349, 10.1074/jbc.M807761200 Ng, 2006, Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin, J Cell Biol, 172, 245, 10.1083/jcb.200503021 Vasiliev, 2013, Regulatory functions of microtubules, Biochemistry (Mosc), 78, 37, 10.1134/S0006297913010045 Nakaya, 2008, RhoA and microtubule dynamics control cell-basement membrane interaction in EMT during gastrulation, Nat Cell Biol, 10, 765, 10.1038/ncb1739 Oyanagi, 2012, Epithelial-mesenchymal transition stimulates human cancer cells to extend microtubule-based invasive protrusions and suppresses cell growth in collagen gel, PLoS One, 7, e53209, 10.1371/journal.pone.0053209 Li, 2011, Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules, Proc Natl Acad Sci U S A, 108, 12851, 10.1073/pnas.1017372108 Ringhoff, 2009, Gene expression profiles in mouse embryo fibroblasts lacking stathmin, a microtubule regulatory protein, reveal changes in the expression of genes contributing to cell motility, BMC Genomics, 10, 343, 10.1186/1471-2164-10-343 Singer, 2009, Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer, Cancer Res, 69, 2234, 10.1158/0008-5472.CAN-08-3338 Belletti, 2008, Stathmin activity influences sarcoma cell shape, motility, and metastatic potential, Mol Biol Cell, 19, 2003, 10.1091/mbc.E07-09-0894 Lee, 2006, The epithelial-mesenchymal transition: new insights in signaling, development, and disease, J Cell Biol, 172, 973, 10.1083/jcb.200601018 Singh, 2010, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer, Oncogene, 29, 4741, 10.1038/onc.2010.215 Sarkar, 2009, Pancreatic cancer stem cells and EMT in drug resistance and metastasis, Minerva Chir, 64, 489 Rhim, 2012, EMT and dissemination precede pancreatic tumor formation, Cell, 148, 349, 10.1016/j.cell.2011.11.025 Chu, 2007, Stromal biology of pancreatic cancer, J Cell Biochem, 101, 887, 10.1002/jcb.21209 Avila, 1992, Microtubule functions, Life Sci, 50, 327, 10.1016/0024-3205(92)90433-P Minton, 2013, Mitosis: Microtubule nucleation branches out, Nat Rev Mol Cell Biol, 14, 192, 10.1038/nrm3550 Zhu, 2009, Mechanism, function and regulation of microtubule-dependent microtubule amplification in mitosis, Mol Cells, 27, 1, 10.1007/s10059-009-0014-2 Guzik, 2004, Microtubule-dependent transport in neurons: steps towards an understanding of regulation, function and dysfunction, Curr Opin Cell Biol, 16, 443, 10.1016/j.ceb.2004.06.002 Scholey, 1990, Cell motility: multiple microtubule motors, Nature, 343, 118, 10.1038/343118a0 Satir, 1990, Microtubule-based cell motility: the role of microtubules in cell motility and differentiation, Cancer Invest, 8, 685, 10.3109/07357909009018945 Risinger, 2009, Microtubule dynamics as a target in oncology, Cancer Treat Rev, 35, 255, 10.1016/j.ctrv.2008.11.001 Lopez-Fanarraga, 2001, Review: postchaperonin tubulin folding cofactors and their role in microtubule dynamics, J Struct Biol, 135, 219, 10.1006/jsbi.2001.4386 Wade, 2009, On and around microtubules: an overview, Mol Biotechnol, 43, 177, 10.1007/s12033-009-9193-5 Dent, 2003, Cytoskeletal dynamics and transport in growth cone motility and axon guidance, Neuron, 40, 209, 10.1016/S0896-6273(03)00633-0 Quiniou, 2013, An atomistic view of microtubule stabilization by GTP, Structure, 21, 833, 10.1016/j.str.2013.03.009 Bowne-Anderson, 2013, Microtubule dynamic instability: a new model with coupled GTP hydrolysis and multistep catastrophe, Bioessays, 35, 452, 10.1002/bies.201200131 Beghin, 2007, Tubulin folding pathways: implication in the regulation of microtubule dynamics, Curr Cancer Drug Targets, 7, 697, 10.2174/156800907783220426 Walczak, 2000, Microtubule dynamics and tubulin interacting proteins, Curr Opin Cell Biol, 12, 52, 10.1016/S0955-0674(99)00056-3 McNally, 1999, Microtubule dynamics: Controlling split ends, Curr Biol, 9, R274, 10.1016/S0960-9822(99)80177-8 Belmont, 1996, Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules, Cell, 84, 623, 10.1016/S0092-8674(00)81037-5 Curmi, 1997, The stathmin/tubulin interaction in vitro., J Biol Chem, 272, 25029, 10.1074/jbc.272.40.25029 Howell, 1999, Dissociation of the tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 18/stathmin, Mol Biol Cell, 10, 105, 10.1091/mbc.10.1.105 Cassimeris, 2002, The oncoprotein 18/stathmin family of microtubule destabilizers, Curr Opin Cell Biol, 14, 18, 10.1016/S0955-0674(01)00289-7 Melander Gradin, 1997, Regulation of microtubule dynamics by Ca2+/calmodulin-dependent kinase IV/Gr-dependent phosphorylation of oncoprotein 18, Mol Cell Biol, 17, 3459, 10.1128/MCB.17.6.3459 Marklund, 1993, Serine 25 of oncoprotein 18 is a major cytosolic target for the mitogen-activated protein kinase, J Biol Chem, 268, 15039, 10.1016/S0021-9258(18)82435-8 Beretta, 1993, Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2, J Biol Chem, 268, 20076, 10.1016/S0021-9258(20)80696-6 Manna, 2009, Regulation of microtubule dynamic instability in vitro by differentially phosphorylated stathmin, J Biol Chem, 284, 15640, 10.1074/jbc.M900343200 Jourdain, 1997, Stathmin: a tubulin-sequestering protein which forms a ternary T2S complex with two tubulin molecules, Biochemistry, 36, 10817, 10.1021/bi971491b Gigant, 2003, The stathmin-tubulin interaction and the regulation of the microtubule assembly, Pathol Biol (Paris), 51, 33, 10.1016/S0369-8114(02)00324-3 Küntziger, 2001, Stathmin/Op18 phosphorylation is regulated by microtubule assembly, Mol Biol Cell, 12, 437, 10.1091/mbc.12.2.437 Melhem, 1997, Quantitative analysis of Op18 phosphorylation in childhood acute leukemia, Leukemia, 11, 1690, 10.1038/sj.leu.2400792 Sellin, 2008, Op18/Stathmin counteracts the activity of overexpressed tubulin-disrupting proteins in a human leukemia cell line, Exp Cell Res, 314, 1367, 10.1016/j.yexcr.2007.12.018 Meyer, 1992, Prolactin-induced proliferation of the Nb2 T-lymphoma is associated with protein kinase-C-independent phosphorylation of stathmin, Endocrinology, 131, 1977, 10.1210/endo.131.4.1396341 Wang, 2010, Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway, Cancer Biol Ther, 10, 632, 10.4161/cbt.10.6.12654 Xi, 2009, Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients, J Cancer Res Clin Oncol, 135, 837, 10.1007/s00432-008-0520-1 Bièche, 1998, Overexpression of the stathmin gene in a subset of human breast cancer, Br J Cancer, 78, 701, 10.1038/bjc.1998.565 Brattsand, 2000, Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors, Br J Cancer, 83, 311, 10.1054/bjoc.2000.1264 Baquero, 2012, Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer, Cancer, 118, 4660, 10.1002/cncr.27453 Mistry, 2005, Targeting stathmin in prostate cancer, Mol Cancer Ther, 4, 1821, 10.1158/1535-7163.MCT-05-0215 Ghosh, 2007, Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression, Prostate, 67, 1038, 10.1002/pros.20601 Zhang, 2004, Significance of stathmin gene overexpression in osteosarcoma cells, Ai Zheng, 23, 493 Ji, 1993, Epidermal growth factor induces serine phosphorylation of stathmin in a human colon carcinoma cell line (LIM 1215), J Biol Chem, 268, 13396, 10.1016/S0021-9258(19)38664-8 Tan, 2012, Proteomic analysis of colorectal cancer metastasis: stathmin-1 revealed as a player in cancer cell migration and prognostic marker, J Proteome Res, 11, 1433, 10.1021/pr2010956 Lin, 2009, Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis, Urology, 74, 1264, 10.1016/j.urology.2009.04.088 Yuan, 2006, Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma, J Pathol, 209, 549, 10.1002/path.2011 Kouzu, 2006, Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis, Br J Cancer, 94, 717, 10.1038/sj.bjc.6602991 Kuo, 2009, High expression of stathmin protein predicts a fulminant course in medulloblastoma, J Neurosurg Pediatr, 4, 74, 10.3171/2009.2.PEDS08287 Nakashima, 2006, Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands, Int J Cancer, 118, 704, 10.1002/ijc.21318 Cassimeris, 1999, Accessory protein regulation of microtubule dynamics throughout the cell cycle, Curr Opin Cell Biol, 11, 134, 10.1016/S0955-0674(99)80017-9 Ringhoff, 2009, Stathmin regulates centrosomal nucleation of microtubules and tubulin dimer/polymer partitioning, Mol Biol Cell, 20, 3451, 10.1091/mbc.E09-02-0140 Luo, 1994, Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase, J Biol Chem, 269, 10312, 10.1016/S0021-9258(17)34062-0 Brattsand, 1994, Cell-cycle-regulated phosphorylation of oncoprotein 18 on Ser16, Ser25 and Ser38, Eur J Biochem, 220, 359, 10.1111/j.1432-1033.1994.tb18632.x Marklund, 1996, Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics, EMBO J, 15, 5290, 10.1002/j.1460-2075.1996.tb00914.x Rubin, 2004, The role of stathmin in the regulation of the cell cycle, J Cell Biochem, 93, 242, 10.1002/jcb.20187 Mistry, 2001, Stathmin inhibition enhances okadaic acid-induced mitotic arrest: a potential role for stathmin in mitotic exit, J Biol Chem, 276, 31209, 10.1074/jbc.M011654200 Alli, 2007, Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53, Oncogene, 26, 1003, 10.1038/sj.onc.1209864 Sonego, 2013, Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer, EMBO Mol Med, 5, 707, 10.1002/emmm.201201504 Johnsen, 2000, p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest, Int J Cancer, 88, 685, 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z Carney, 2010, Stathmin/oncoprotein 18, a microtubule regulatory protein, is required for survival of both normal and cancer cell lines lacking the tumor suppressor, p53, Cancer Biol Ther, 9, 699, 10.4161/cbt.9.9.11430 Doye, 1992, High expression of stathmin in multipotential teratocarcinoma and normal embryonic cells versus their early differentiated derivatives, Differentiation, 50, 89, 10.1111/j.1432-0436.1992.tb00489.x Koppel, 1990, Developmental tissue expression and phylogenetic conservation of stathmin, a phosphoprotein associated with cell regulations, J Biol Chem, 265, 3703, 10.1016/S0021-9258(19)39651-6 Doye, 1992, Expression of transfected stathmin cDNA reveals novel phosphorylated forms associated with developmental and functional cell regulation, Biochem J, 287, 549, 10.1042/bj2870549 Koppel, 1993, Induction of stathmin expression during liver regeneration, FEBS Lett, 331, 65, 10.1016/0014-5793(93)80298-9 Okazaki, 1993, Induction of stathmin mRNA during liver regeneration, FEBS Lett, 336, 8, 10.1016/0014-5793(93)81598-T Andersen, 2010, Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors, Sci Transl Med, 2, 43ra55, 10.1126/scitranslmed.3001065 Karst, 2011, Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas, Gynecol Oncol, 123, 5, 10.1016/j.ygyno.2011.05.021 Etienne-Manneville, 2004, Actin and microtubules in cell motility: which one is in control?, Traffic, 5, 470, 10.1111/j.1600-0854.2004.00196.x Huse, 2006, T cells use two directionally distinct pathways for cytokine secretion, Nat Immunol, 7, 247, 10.1038/ni1304 Stinchcombe, 2006, Centrosome polarization delivers secretory granules to the immunological synapse, Nature, 443, 462, 10.1038/nature05071 Stinchcombe, 2001, The immunological synapse of CTL contains a secretory domain and membrane bridges, Immunity, 15, 751, 10.1016/S1074-7613(01)00234-5 Filbert, 2012, Stathmin regulates microtubule dynamics and microtubule organizing center polarization in activated T cells, J Immunol, 188, 5421, 10.4049/jimmunol.1200242 Matesanz, 2011, Modulation of microtubule interprotofilament interactions by modified taxanes, Biophys J, 101, 2970, 10.1016/j.bpj.2011.11.005 Cortes, 2012, Beyond taxanes: the next generation of microtubule-targeting agents, Breast Cancer Res Treat, 133, 821, 10.1007/s10549-011-1875-6 Warfield, 1974, Microtubule-macrotubule transitions: intermediates after exposure to the mitotic inhibitor vinblastine, Science, 186, 1219, 10.1126/science.186.4170.1219 Sajó, 1977, Vinblastine inhibition of microtubule assembly in vitro., Acta Biochim Biophys Acad Sci Hung, 12, 259 Morgan, 1987, Vinblastine but not other microtubule inhibitors block transferrin endocytosis and iron uptake by reticulocytes, Clin Exp Pharmacol Physiol, 14, 119, 10.1111/j.1440-1681.1987.tb00965.x Durkó, 1990, Effects of two microtubule-depolymerizing drugs, vincristine and vinblastine, on porphyrin production by primary neural tissue cultures, Neurochem Res, 15, 1135, 10.1007/BF01101716 Alli, 2002, Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer, Cancer Res, 62, 6864 Benner, 1997, Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies, J Pharmacol Toxicol Methods, 37, 229, 10.1016/S1056-8719(97)00034-8 Kalluri, 2009, EMT: when epithelial cells decide to become mesenchymal-like cells, J Clin Invest, 119, 1417, 10.1172/JCI39675 López-Novoa, 2009, Inflammation and EMT: an alliance towards organ fibrosis and cancer progression, EMBO Mol Med, 1, 303, 10.1002/emmm.200900043 Zhou, 2012, Inflammation linking EMT and cancer stem cells, Oral Oncol, 48, 1068, 10.1016/j.oraloncology.2012.06.005 Hofman, 2012, Microbes-induced EMT at the crossroad of inflammation and cancer, Gut Microbes, 3, 176, 10.4161/gmic.20288 Neilson, 2006, Mechanisms of disease: Fibroblasts–a new look at an old problem, Nat Clin Pract Nephrol, 2, 101, 10.1038/ncpneph0093 Kalluri, 2003, Epithelial-mesenchymal transition and its implications for fibrosis, J Clin Invest, 112, 1776, 10.1172/JCI200320530 Kang, 2004, Epithelial-mesenchymal transitions: twist in development and metastasis, Cell, 118, 277, 10.1016/j.cell.2004.07.011 Peinado, 2007, Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?, Nat Rev Cancer, 7, 415, 10.1038/nrc2131 Acloque, 2009, Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease, J Clin Invest, 119, 1438, 10.1172/JCI38019 Kalluri, 2009, The basics of epithelial-mesenchymal transition, J Clin Invest, 119, 1420, 10.1172/JCI39104 Stracke, 1991, Cell motility, a principal requirement for metastasis, EXS, 59, 147 Guarino, 2007, Epithelial-mesenchymal transition and tumour invasion, Int J Biochem Cell Biol, 39, 2153, 10.1016/j.biocel.2007.07.011 Kee, 2001, Microtubule disruption in keratinocytes induces cell-cell adhesion through activation of endogenous E-cadherin, Mol Biol Cell, 12, 1983, 10.1091/mbc.12.7.1983 Yang, 2006, Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines, Clin Cancer Res, 12, 4147, 10.1158/1078-0432.CCR-06-0038 Arumugam, 2009, Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer, Cancer Res, 69, 5820, 10.1158/0008-5472.CAN-08-2819 Li, 2009, Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells, Clin Cancer Res, 15, 2657, 10.1158/1078-0432.CCR-08-2372 Shi, 2012, Combinational therapy: new hope for pancreatic cancer?, Cancer Lett, 317, 127, 10.1016/j.canlet.2011.11.029 Nemunaitis, 2012, Stathmin 1: a protein with many tasks. New biomarker and potential target in cancer, Expert Opin Ther Targets, 16, 631, 10.1517/14728222.2012.696101 Rana, 2008, Stathmin 1: a novel therapeutic target for anticancer activity, Expert Rev Anticancer Ther, 8, 1461, 10.1586/14737140.8.9.1461 Dong, 2012, Stathmin expression in glioma-derived microvascular endothelial cells: a novel therapeutic target, Oncol Rep, 27, 714 Shintani, 2011, Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer, Ann Thorac Surg, 92, 1794, 10.1016/j.athoracsur.2011.07.032 Foroni, 2012, Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact, Cancer Treat Rev, 38, 689, 10.1016/j.ctrv.2011.11.001 Liu, 2013, MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3, Curr Mol Med, 13, 467, 10.2174/1566524011313040001